OTCM
RICFY
Market cap11bUSD
Jun 18, Last price
14.52USD
1D
0.00%
1Q
21.10%
Name
Recordati Industria Chimica e Farmaceutica SpA
Chart & Performance
P/E
6.24
P/S
1.11
EPS
2.03
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
9.58%
Revenues
2.34b
+12.45%
Net income
417m
+7.01%
CFO
570m
+17.43%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Recordati Industria Chimica e Farmaceutica S.p.A., alongside its global subsidiaries, is actively involved in the discovery, formulation, production, promotion, and distribution of pharmaceutical products worldwide. Its extensive portfolio addresses a broad spectrum of medical needs, encompassing treatments for cardiovascular conditions, dermatological issues, urological problems, and infections. The firm also develops solutions for central nervous system disorders, gastrointestinal health, women's health (gynecology and obstetrics), musculoskeletal ailments, and pain relief. Additionally, Recordati provides a range of over-the-counter medications, allergy treatments, endocrine therapies, respiratory drugs, oncology products, and remedies for ear, nose, and throat conditions. Beyond prescription drugs, the company offers nutrition-related items, cosmetics, dietary supplements, medical devices, generic drugs, antipyretics, and cold preparations. Moreover, the company is dedicated to offering therapies for rare diseases and produces essential pharmaceutical chemicals, including active pharmaceutical ingredients (APIs), intermediate compounds, and undertaking chemical syntheses. Established in Milan, Italy, in 1926, Recordati Industria Chimica e Farmaceutica S.p.A. currently operates as a subsidiary of Rossini S.à R.L.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||